Share Buyback

Beyond a simple payout, Amerigo Resources’ latest dividend reveals a powerful strategy of innovation, financial discipline, and a bullish copper market.

Gossamer Bio's recent 200,000-share grant to a new hire is more than a welcome bonus; it's a strategic bet on its blockbuster drug candidate.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Beyond a simple transaction, Foresight Group's ongoing share repurchase signals deep confidence and a commitment to disciplined capital management.

Progressive's massive dividend signals immense financial strength, but what does this capital return strategy mean for its innovation and digital future?

A simple phone line delivers messages from resilient kids. We decode the powerful science showing how these wishes improve health and drive recovery.

Emera renewed its C$600M equity program. We dive into the $20B plan driving this move and what it means for the future of energy grids and investors.

Pershing Square's latest share repurchase is more than routine; it's a strategic move to close a stubborn valuation gap and signal deep confidence.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.

Immunome is using strategic stock grants to lure top talent. We analyze why this move is critical for its pipeline and what it means for investors.

A class action lawsuit against Telix Pharmaceuticals reveals the perilous gap between optimistic corporate disclosures and harsh regulatory setbacks.

Danone's latest share buyback isn't just a financial maneuver. It’s a strategic move to boost employee ownership while protecting shareholder value.